Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C22H22FN3O2.C3H6O3 |
| Molecular Weight | 469.5053 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)C(O)=O.FC1=CC=C(C=C1)C(=O)CCCN2CCC(=CC2)N3C(=O)NC4=CC=CC=C34
InChI
InChIKey=CUYSTLHETVVORS-UHFFFAOYSA-N
InChI=1S/C22H22FN3O2.C3H6O3/c23-17-9-7-16(8-10-17)21(27)6-3-13-25-14-11-18(12-15-25)26-20-5-2-1-4-19(20)24-22(26)28;1-2(4)3(5)6/h1-2,4-5,7-11H,3,6,12-15H2,(H,24,28);2,4H,1H3,(H,5,6)
DescriptionSources: http://www.drugbank.ca/drugs/DB00450Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/droperidol.html
Sources: http://www.drugbank.ca/drugs/DB00450
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/droperidol.html
Droperidol produces marked tranquilization and sedation. It allays apprehension and provides a state of mental detachment and indifference while maintaining a state of reflex alertness. Droperidol produces an antiemetic effect as evidenced by the antagonism of apomorphine in dogs. It lowers the incidence of nausea and vomiting during surgical procedures and provides antiemetic protection in the postoperative period. Droperidol potentiates other CNS depressants. It produces mild alpha-adrenergic blockade, peripheral vascular dilatation and reduction of the pressor effect of epinephrine. It can produce hypotension and decreased peripheral vascular resistance and may decrease pulmonary arterial pressure (particularly if it is abnormally high). It may reduce the incidence of epinephrine-induced arrhythmias, but it does not prevent other cardiac arrhythmias. The exact mechanism of action is unknown, however, droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation. It may antagonize the actions of glutamic acid within the extrapyramidal system. It may also inhibit cathecolamine receptors and the reuptake of neurotransmiters and has strong central antidopaminergic action and weak central anticholinergic action. It can also produce ganglionic blockade and reduced affective response. The main actions seem to stem from its potent Dopamine (2) receptor antagonism with minor antagonistic effects on alpha-1 adrenergic receptors as well. Droperidol is used to produce tranquilization and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures.
CNS Activity
Sources: http://www.drugbank.ca/drugs/DB00450
Curator's Comment: Droperidol causes a CNS depression at subcortical levels of the brain, midbrain, and brainstem reticular formation.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 Sources: http://www.drugbank.ca/drugs/DB00450 |
|||
Target ID: CHEMBL229 Sources: http://www.drugbank.ca/drugs/DB00450 |
|||
Target ID: CHEMBL240 |
32.2 nM [IC50] | ||
Target ID: CHEMBL224 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Secondary | INAPSINE Approved UseDroperidol injection is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures. Launch Date1970 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
6.5 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
26.6 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
18.7 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
40 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, nasal dose: 0.02 mg/kg route of administration: Nasal experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
2.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30574300/ |
0.02 mg/kg single, intravenous dose: 0.02 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DROPERIDOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.4 mg/kg multiple, oral Dose: 0.4 mg/kg Route: oral Route: multiple Dose: 0.4 mg/kg Sources: |
unhealthy, 2-9 years Health Status: unhealthy Age Group: 2-9 years Sources: |
Disc. AE: QT interval prolonged... AEs leading to discontinuation/dose reduction: QT interval prolonged Sources: |
8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
Other AEs: Asthenia, Chills... Other AEs: Asthenia (24.6%) Sources: Chills (3.3%) Anorexia (3.3%) Akathisia (16.4%) Anxiety (27.9%) Confusion (3.3%) Dizziness (9.8%) Dry mouth (9.8%) Nervousness (4.9%) Paresthesia (3.3%) Somnolence (24.6%) Tremor (1.6%) Pharyngitis (4.9%) Rhinitis (4.9%) Sweaty (8.2%) |
2.5 mg multiple, intravenous (starting) Dose: 2.5 mg Route: intravenous Route: multiple Dose: 2.5 mg Sources: |
unhealthy |
Disc. AE: Torsades de pointes... AEs leading to discontinuation/dose reduction: Torsades de pointes Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| QT interval prolonged | Disc. AE | 0.4 mg/kg multiple, oral Dose: 0.4 mg/kg Route: oral Route: multiple Dose: 0.4 mg/kg Sources: |
unhealthy, 2-9 years Health Status: unhealthy Age Group: 2-9 years Sources: |
| Tremor | 1.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Akathisia | 16.4% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Asthenia | 24.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Somnolence | 24.6% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Anxiety | 27.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Anorexia | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Chills | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Confusion | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Paresthesia | 3.3% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Nervousness | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Pharyngitis | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Rhinitis | 4.9% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Sweaty | 8.2% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Dizziness | 9.8% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Dry mouth | 9.8% | 8.25 mg single, intramuscular Highest studied dose Dose: 8.25 mg Route: intramuscular Route: single Dose: 8.25 mg Sources: |
unhealthy, 42 ± 10.0 years n = 61 Health Status: unhealthy Condition: acute migraine headache Age Group: 42 ± 10.0 years Sex: M+F Population Size: 61 Sources: |
| Torsades de pointes | Disc. AE | 2.5 mg multiple, intravenous (starting) Dose: 2.5 mg Route: intravenous Route: multiple Dose: 2.5 mg Sources: |
unhealthy |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes |
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| major | ||||
| major |
Tox targets
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Extrapyramidal side-effects from droperidol mixed with morphine for patient-controlled analgesia in two children. | 1999 |
|
| Droperidol for acute psychosis. | 2001 |
|
| Placebo-controlled comparison of dolasetron and metoclopramide in preventing postoperative nausea and vomiting in patients undergoing hysterectomy. | 2001 Apr |
|
| A small dose of droperidol decreases postoperative nausea and vomiting in adults but cannot improve an already excellent patient satisfaction. | 2001 Apr |
|
| Ondansetron versus dehydrobenzoperidol and metoclopramide for management of postoperative nausea in laparoscopic surgery patients. | 2001 Apr-Jun |
|
| Preparation, premedication, and surveillance. | 2001 Feb |
|
| [Prevention of postoperative nausea and vomiting in gynecologic surgery with 3 fixed doses of metoclopramide, droperidol or placebo]. | 2001 Feb |
|
| Evaluation of the effective drugs for the prevention of nausea and vomiting induced by morphine used for postoperative pain: a quantitative systematic review. | 2001 Feb |
|
| The effect of betahistine on vestibular habituation: comparison of rotatory and sway habituation training. | 2001 Jul |
|
| Plasma glucocorticoid concentrations after fentanyl-droperidol, ketamine-xylazine and ketamine-diazepam anaesthesia in New Zealand white rabbits. | 2001 Jun 23 |
|
| Optimising management of delirium. Withdrawal of Droleptan (droperidol). | 2001 Jun 30 |
|
| The Expert Consensus Guideline Series. Treatment of behavioral emergencies. | 2001 May |
|
| Impact of antiemetic selection on postoperative nausea and vomiting and patient satisfaction. | 2001 May |
|
| IM droperidol as premedication attenuates intraoperative hypothermia. | 2001 Oct |
|
| [Postoperative nausea--still a problem]. | 2001 Oct 3 |
|
| [Continuous epidural administration of droperidol for the prevention of postoperative nausea]. | 2001 Sep |
|
| Droperidol inhibits GABA(A) and neuronal nicotinic receptor activation. | 2002 Apr |
|
| Droperidol: cardiovascular toxicity and deaths. | 2002 Apr 2 |
|
| P6 acupoint injections are as effective as droperidol in controlling early postoperative nausea and vomiting in children. | 2002 Aug |
|
| [Droperidol causes multifocal ventricular dysrhythmias]. | 2002 Jan |
|
| A randomized clinical trial to assess the efficacy of intramuscular droperidol for the treatment of acute migraine headache. | 2002 Jan |
|
| Premedication, preparation, and surveillance. | 2002 Jan |
|
| Effects of sevoflurane on electrocorticography in patients with intractable temporal lobe epilepsy. | 2002 Jan |
|
| Monocomponent chemoembolization in oral and oropharyngeal cancer using an aqueous crystal suspension of cisplatin. | 2002 Jan 21 |
|
| The FDA droperidol warning: is it justified? | 2002 Jul |
|
| Droperidol "box warning" warrants scrutiny. | 2002 Jul |
|
| FDA "black box" warning regarding use of droperidol for postoperative nausea and vomiting: is it justified? | 2002 Jul |
|
| Gateways to Clinical Trials. June 2002. | 2002 Jun |
|
| Intramuscular droperidol versus intramuscular dimenhydrinate for the treatment of acute peripheral vertigo in the emergency department: a randomized clinical trial. | 2002 Jun |
|
| [Effects of preincisional epidural administration of lidocaine and fentanyl on postoperative pain management following hysterectomy]. | 2002 Jun 10 |
|
| Arrhythmias from droperidol? | 2002 Jun 10 |
|
| Continuous epidural, not intravenous, droperidol inhibits pruritus, nausea, and vomiting during epidural morphine analgesia. | 2002 Mar |
|
| Using imprecise probabilities to address the questions of inference and decision in randomized clinical trials. | 2002 May |
|
| Psychotropic drugs and the ECG: focus on the QTc interval. | 2002 May |
|
| Effects of clonidine on postoperative nausea and vomiting in breast cancer surgery. | 2002 May |
|
| LC determination and degradation study of droperidol. | 2002 May 15 |
|
| The addition of antiemetics to the morphine solution in patient controlled analgesia syringes used by children after an appendicectomy does not reduce the incidence of postoperative nausea and vomiting. | 2002 Sep |
Patents
Sample Use Guides
Dosage: The dosage should be individualized. Factors to be considered in determining dose are age, body weight, physical status, underlying pathological condition, use of other drugs, the type of anesthesia to be used, and the surgical procedure involved. Vital signs and ECG should be monitored closely.
Maximum Dosage: The maximum recommended initial dose is 2.5 mg IM or slow IV. Additional 1.25 mg doses of droperidol may be administered to achieve the desired effect. The additional doses should be administered with caution and only if the potential benefit outweighs the potential risk.
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB01839MIG
Created by
admin on Sat Dec 16 09:00:02 GMT 2023 , Edited by admin on Sat Dec 16 09:00:02 GMT 2023
|
PRIMARY | |||
|
9956314
Created by
admin on Sat Dec 16 09:00:02 GMT 2023 , Edited by admin on Sat Dec 16 09:00:02 GMT 2023
|
PRIMARY | |||
|
09NO5N37E0
Created by
admin on Sat Dec 16 09:00:02 GMT 2023 , Edited by admin on Sat Dec 16 09:00:02 GMT 2023
|
PRIMARY | |||
|
100000087719
Created by
admin on Sat Dec 16 09:00:02 GMT 2023 , Edited by admin on Sat Dec 16 09:00:02 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
